

Sub-par margin; near-term weakness in top client to weigh on growth

Information Technology ▶ Result Update ▶ January 17, 2025

TARGET PRICE (Rs): 6,000

LTIM reported a mixed performance in Q3FY25; revenue growth of 1.8% QoQ CC was in line with our estimate, while EBITM of 13.8% fell slightly short of our expectations. Deal wins of USD1.7bn (book-to-bill: ~1.5x) was the highest ever, supported by large deals, vendor consolidation, and deal renewals, particularly in BFSI. The deal pipeline continues to be dominated by cost reduction and vendor consolidation. The management expects growth momentum to sustain in Q4 on the back of deal ramp-up, partial reversal of furloughs, and continued strength in BFS, though partly offset by near-term headwinds from AI-driven productivity in the top client and lesser working days. Discretionary spending has improved in select pockets of BFS (regulatory space), though broad-based spends are yet to rebound in a secular manner. Based on recent deal-wins and pipeline, FY26 is expected to be better than FY25, with focus maintained on profitable growth. We tweak FY25-27E EPS by 1.2-1.8%, considering the Q3 performance; retain REDUCE and TP of Rs6,000 at 28x Dec-26E EPS.

LTIMindtree: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	331,830	355,170	381,183	422,875	479,597
EBITDA	61,077	63,874	66,379	77,688	90,506
Adj. PAT	44,083	45,821	46,807	55,045	65,272
Adj. EPS (Rs)	149.0	154.8	158.0	185.8	220.4
EBITDA margin (%)	18.4	18.0	17.4	18.4	18.9
EBITDA growth (%)	16.4	4.6	3.9	17.0	16.5
Adj. EPS growth (%)	11.6	3.9	2.1	17.6	18.6
RoE (%)	26.6	25.0	21.9	22.6	23.5
RoIC (%)	53.8	51.5	44.6	48.8	54.3
P/E (x)	40.1	38.6	37.8	32.2	27.1
EV/EBITDA (x)	28.6	27.4	26.4	22.4	19.1
P/B (x)	10.7	8.8	7.8	6.8	6.0
FCFF yield (%)	1.2	2.7	2.0	2.9	3.2

Source: Company, Emkay Research

Results Summary

Revenue grew 1.1% QoQ (1.8% CC) to USD1.14bn, similar to our estimate of 1.8% CC growth. EBITM declined by 170bps QoQ to 13.8%, slightly lower than our estimate of 14%. EBITM was negatively impacted by wage hikes (-220bps) and partially offset by ongoing efforts on cost optimization (50bps). All industries saw decline in their operating margins sequentially. Ttop-5 clients' revenue declined 0.7% QoQ, while the top 6-10 clients saw growth of 1.1% QoQ. North America and ROW saw growth of 0.7% and 9% QoQ, respectively, in USD terms, while Europe declined 2.7% (CC 3% growth). Among verticals, BFSI and Manufacturing & Resources saw growth of 3.4% and 8.1% QoQ, while CMT, Consumer, and Healthcare, Lifesciences & Public Services declined 5.8%, 0.7%, and 0.2% QoQ, respectively. TTM attrition – saw a marginal dip to 14.3% from 14.5%, in Q2FY25. Total headcount grew 2.8% QoQ to 86,800. Utilization (excl trainees) declined from 87.7% in Q2 to 85.4% in Q3. **What we liked:** Strong deal intake, healthy cash conversion (OCF/EBITDA 86%). **What we did not like:** Margin miss, weakness in top client.

Earnings Call KTAs

1) LTIM won record deal wins (worth USD1.68bn, up 29% QoQ), which include a new logo worth over USD50mn in Manufacturing, and two large deals in the BFSI vertical. 2) Technology declined 5.5% CC QoQ due to pass-through of AI-driven productivity benefit at the top client. The mgmt indicated that this caused an impact for 2 months in Q3, and that the full-quarter impact will reflect in Q4 numbers. The mgmt stated that impact on margin will be neutral from passing-on of productivity benefits. 3) It expects margins to improve in Q4, though full impact of absorbing the wage hikes may take longer in the current growth environment. Margin improvement continues to be a growth factor. 4) AI spends have started shifting from proof of concept to scale projects in select areas as well as foundational data and infrastructure. Savings from cost reduction and vendor consolidation programs are being deployed in pilot programs and for scaling AI initiatives. 5) Utilization comfort-range remains at 85-86%. Q4 would see improvement in utilization which should aid margin. Ahead, utilization and hiring should remain a function of market conditions and demand environment. 6) Manufacturing has seen good momentum, with LTIM signing a couple of large deals. It has lower exposure to Auto, and is considerably engaged in Industrial Manufacturing. 7) LTIM added 1,400 freshers in Q3.


Target Price – 12M	Dec-25
Change in TP (%)	-
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	0.4
CMP (16-Jan-25) (Rs)	5,978.8

Stock Data	Ticker
52-week High (Rs)	6,768
52-week Low (Rs)	4,514
Shares outstanding (mn)	296.3
Market-cap (Rs bn)	1,771
Market-cap (USD mn)	20,467
Net-debt, FY25E (Rs mn)	-20,892
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	2,033.6
ADTV-3M (USD mn)	23.5
Free float (%)	31.0
Nifty-50	23,312
INR/USD	86.6
Shareholding, Sep-24	
Promoters (%)	68.6
FPIs/MFs (%)	7.4/14.9

Price Performance

(%)	1M	3M	12M
Absolute	(11.3)	(6.0)	(4.1)
Rel. to Nifty	(6.1)	0.7	(9.4)

1-Year share price trend (Rs)



Dipesh Mehta

dipeshkumar.mehta@emkayglobal.com
+91 22 6612 1253

Pulkit Chawla

pulkit.chawla@emkayglobal.com
+91 22 6624 2458

Kevin Shah

kevin.shah@emkayglobal.com
+91 22 6612 1340

Shivang Bagla

shivang.bagla@emkayglobal.com
+91 22 6624 2491

Exhibit 1: Quarterly snapshot

(Rs mn)	Q3FY25	Q2FY25	QoQ (%)	Q3FY24	YoY (%)
Revenue (USD)	1,139	1,127	1.1	1,084	5.1
Net sales	96,609	94,329	2.4	90,166	7.1
Operating expenses	80,676	77,336		74,317	
EBITDA	15,933	16,993	-6.2	15,849	0.5
Margins (%)	16.5	18.0	-150.0	17.6	(110.0)
Depreciation	2,644	2,411		1,990	
EBIT	13,289	14,582	-8.9	13,859	-4.1
Margins (%)	13.8	15.5	-170	15.4	(160.0)
Forex Gains/(Losses)	132	751		426	
Other income	1,304	1,535		1162	
Pre-tax profit	14,725	16,868	-12.7	15,447	-4.7
Tax provided	3,858	4,352		3,754	
Profit after tax	10,867	12,516		11,693	
Emkay Net profit	10,854	12,510	-13.2	11,689	-7.1
EPS (Rs)	36.6	42.3	-13.3	39.5	-7.2

Source: Company, Emkay Research

Exhibit 2: Actuals vs estimates

	Actual	Estimate		Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Sales (USD mn)	1,139	1,142	1,123	-0.3%	1.4%	Revenue was in line with our expectations.
Sales (Rs mn)	96,609	96,645	96,485	0.0%	0.1%	
EBIT (Rs mn)	13,289	13,575	13,668	-2.1%	-2.8%	Margins came in lower than our expectations.
EBIT margin	13.8%	14.0%	14.2%	-30 bps	-40 bps	
PAT (Rs mn)	10,854	11,248	11,491	-3.5%	-5.5%	PAT missed expectations due to margin miss and higher ETR.


Source: Company, Bloomberg, Emkay Research

Exhibit 3: Changes in estimates

	FY25E			FY26E			FY27E		
	Old	New	Change	Old	New	Change	Old	New	Change
Revenue (USD mn)	4,530	4,517	-0.3%	5,007	4,946	-1.2%	5,585	5,513	-1.3%
YoY growth (%)	5.7	5.4		10.5	9.5		11.5	11.5	
Revenue (Rs mn)	382,026	381,183	-0.2%	428,103	422,875	-1.2%	485,866	479,597	-1.3%
EBIT (Rs mn)	56,883	56,323	-1.0%	68,386	66,631	-2.6%	80,168	78,574	-2.0%
EBIT margins (%)	14.9	14.8		16.0	15.8		16.5	16.4	
Net profit (Rs mn)	47,412	46,807		56,047	55,045		66,088	65,272	
EPS (Rs)	160.1	158.0	-1.3%	189.2	185.8	-1.8%	223.1	220.4	-1.2%

Source: Company, Emkay Research

Exhibit 4: LTIM – One-year forward PER



Source: Company, Emkay Research

LTIMindtree: Consolidated Financials and Valuations

Profit & Loss

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	331,830	355,170	381,183	422,875	479,597
Revenue growth (%)	27.1	7.0	7.3	10.9	13.4
EBITDA	61,077	63,874	66,379	77,688	90,506
EBITDA growth (%)	16.4	4.6	3.9	17.0	16.5
Depreciation & Amortization	7,227	8,189	10,056	11,056	11,932
EBIT	53,850	55,685	56,323	66,631	78,574
EBIT growth (%)	15.8	3.4	1.1	18.3	17.9
Other operating income	1,504	2,217	2,805	2,900	2,978
Other income	5,569	7,019	9,587	10,203	12,078
Financial expense	1,504	2,217	2,805	2,900	2,978
PBT	57,915	60,487	63,105	73,934	87,674
Extraordinary items	0	0	0	0	0
Taxes	13,812	14,641	16,260	18,853	22,357
Minority interest	20	25	38	36	45
Income from JV/Associates	0	0	0	0	0
Reported PAT	44,083	45,821	46,807	55,045	65,272
PAT growth (%)	11.7	3.9	2.2	17.6	18.6
Adjusted PAT	44,083	45,821	46,807	55,045	65,272
Diluted EPS (Rs)	149.0	154.8	158.0	185.8	220.4
Diluted EPS growth (%)	11.6	3.9	2.1	17.6	18.6
DPS (Rs)	60.0	65.0	67.0	78.0	93.0
Dividend payout (%)	40.3	42.0	42.4	42.0	42.2
EBITDA margin (%)	18.4	18.0	17.4	18.4	18.9
EBIT margin (%)	16.2	15.7	14.8	15.8	16.4
Effective tax rate (%)	23.8	24.2	25.8	25.5	25.5
NOPLAT (pre-IndAS)	41,007	42,206	41,811	49,640	58,538
Shares outstanding (mn)	295.8	295.9	296.2	296.2	296.2

Source: Company, Emkay Research

Balance Sheet

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	296	296	296	296	296
Reserves & Surplus	165,625	199,876	226,839	258,781	296,509
Net worth	165,921	200,172	227,135	259,077	296,805
Minority interests	71	92	130	166	211
Deferred tax liability (net)	(3,662)	(2,063)	(2,063)	(2,063)	(2,063)
Total debt	0	0	0	0	0
Total liabilities & equity	162,330	198,201	225,202	257,180	294,953
Net tangible fixed assets	9,697	16,555	20,883	20,343	19,910
Net intangible assets	3,560	3,151	2,776	2,282	1,784
Net ROU assets	12,539	19,013	20,224	21,222	22,742
Capital WIP	8,126	4,669	4,669	4,669	4,669
Goodwill	11,892	11,927	11,927	11,927	11,927
Investments [JV/Associates]	54,622	87,502	99,902	119,902	139,902
Cash & equivalents	23,389	18,200	20,892	28,707	38,581
Current assets (ex-cash)	107,327	112,363	124,480	136,105	151,885
Current Liab. & Prov.	68,822	75,179	80,551	87,977	96,446
NWC (ex-cash)	38,505	37,184	43,928	48,128	55,439
Total assets	162,330	198,201	225,202	257,180	294,953
Net debt	(23,389)	(18,200)	(20,892)	(28,707)	(38,581)
Capital employed	162,330	198,201	225,202	257,180	294,953
Invested capital	76,193	87,830	99,738	103,902	111,801
BVPS (Rs)	560.9	676.5	766.9	874.7	1,002.1
Net Debt/Equity (x)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Net Debt/EBITDA (x)	(0.4)	(0.3)	(0.3)	(0.4)	(0.4)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
RoCE (%)	36.6	34.8	31.1	31.9	32.8

Source: Company, Emkay Research

Cash flows

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	57,915	60,487	63,105	73,934	87,674
Others (non-cash items)	5,893	5,940	10,056	11,056	11,932
Taxes paid	(15,217)	(15,707)	(16,260)	(18,853)	(22,357)
Change in NWC	(17,645)	5,975	(6,744)	(4,200)	(7,311)
Operating cash flow	30,946	56,695	50,156	61,938	69,939
Capital expenditure	(9,346)	(8,330)	(15,220)	(11,020)	(12,520)
Acquisition of business	(1,486)	(59)	0	0	0
Interest & dividend income	1,266	2,573	0	0	0
Investing cash flow	(3,309)	(39,121)	(27,620)	(31,020)	(32,520)
Equity raised/(repaid)	2	12	0	0	0
Debt raised/(repaid)	71	(280)	0	0	0
Payment of lease liabilities	(3,388)	(3,761)	0	0	0
Interest paid	(375)	(906)	0	0	0
Dividend paid (incl tax)	(15,627)	(17,753)	(19,844)	(23,102)	(27,545)
Others	0	0	0	0	0
Financing cash flow	(19,317)	(22,688)	(19,844)	(23,102)	(27,545)
Net chg in Cash	8,320	(5,114)	2,692	7,815	9,874
OCF	30,946	56,695	50,156	61,938	69,939
Adj. OCF (w/o NWC chg.)	48,591	50,720	56,901	66,138	77,249
FCFF	21,600	48,365	34,936	50,918	57,419
FCFE	21,362	48,721	32,131	48,018	54,441
OCF/EBITDA (%)	50.7	88.8	75.6	79.7	77.3
FCFE/PAT (%)	48.5	106.3	68.6	87.2	83.4
FCFF/NOPLAT (%)	52.7	114.6	83.6	102.6	98.1

Source: Company, Emkay Research

Valuations and key Ratios

Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	40.1	38.6	37.8	32.2	27.1
P/CE(x)	34.5	32.8	31.1	26.8	22.9
P/B (x)	10.7	8.8	7.8	6.8	6.0
EV/Sales (x)	5.3	4.9	4.6	4.1	3.6
EV/EBITDA (x)	28.6	27.4	26.4	22.4	19.1
EV/EBIT(x)	32.4	31.4	31.1	26.1	22.0
EV/IC (x)	22.9	19.9	17.5	16.8	15.5
FCFF yield (%)	1.2	2.7	2.0	2.9	3.2
FCFE yield (%)	1.2	2.8	1.8	2.7	3.1
Dividend yield (%)	1.0	1.1	1.1	1.3	1.6
DuPont-RoE split					
Net profit margin (%)	13.3	12.9	12.3	13.0	13.6
Total asset turnover (x)	2.0	2.0	1.8	1.8	1.7
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	26.6	25.0	21.9	22.6	23.5
DuPont-RoIC					
NOPLAT margin (%)	12.4	11.9	11.0	11.7	12.2
IC turnover (x)	4.4	4.3	4.1	4.2	4.4
RoIC (%)	53.8	51.5	44.6	48.8	54.3
Operating metrics					
Core NWC days	42.4	38.2	42.1	41.5	42.2
Total NWC days	42.4	38.2	42.1	41.5	42.2
Fixed asset turnover	8.8	8.0	7.2	7.6	8.6
Opex-to-revenue (%)	81.6	82.0	82.6	81.6	81.1


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
01-Jan-25	5,673	6,000	Reduce	Dipeshkumar Mehta
27-Nov-24	6,262	6,100	Reduce	Dipeshkumar Mehta
18-Oct-24	5,992	6,100	Reduce	Dipeshkumar Mehta
01-Oct-24	6,273	6,100	Reduce	Dipeshkumar Mehta
17-Jul-24	5,562	5,250	Reduce	Dipeshkumar Mehta
01-Jul-24	5,448	5,250	Reduce	Dipeshkumar Mehta
03-Jun-24	4,649	5,000	Reduce	Dipeshkumar Mehta
27-May-24	4,892	5,000	Reduce	Dipeshkumar Mehta
25-Apr-24	4,635	5,000	Reduce	Dipeshkumar Mehta
31-Mar-24	4,938	5,100	Reduce	Dipeshkumar Mehta
01-Mar-24	5,274	5,900	Reduce	Dipeshkumar Mehta
18-Jan-24	5,603	5,900	Reduce	Dipeshkumar Mehta
31-Dec-23	6,295	6,250	Reduce	Dipeshkumar Mehta
30-Nov-23	5,537	5,500	Reduce	Dipeshkumar Mehta
19-Oct-23	5,458	5,500	Hold	Dipeshkumar Mehta
02-Oct-23	5,210	5,600	Hold	Dipeshkumar Mehta
17-Jul-23	5,135	4,950	Hold	Dipeshkumar Mehta
02-Jul-23	5,197	4,950	Hold	Dipeshkumar Mehta
28-Apr-23	4,419	4,750	Hold	Dipeshkumar Mehta
01-Apr-23	4,760	4,850	Hold	Dipeshkumar Mehta
15-Mar-23	4,592	4,850	Hold	Dipeshkumar Mehta
21-Jan-23	4,268	4,600	Hold	Dipeshkumar Mehta
02-Jan-23	4,322	4,700	Hold	Dipeshkumar Mehta
12-Dec-22	4,331	4,700	Hold	Dipeshkumar Mehta
15-Oct-22	4,669	4,500	Hold	Dipeshkumar Mehta
04-Oct-22	4,588	4,450	Hold	Dipeshkumar Mehta
15-Jul-22	3,975	4,700	Buy	Dipeshkumar Mehta
23-Jun-22	4,133	4,700	Buy	Dipeshkumar Mehta
07-May-22	4,593	-	UR	Dipeshkumar Mehta
20-Apr-22	5,170	6,350	Hold	Dipeshkumar Mehta
01-Apr-22	6,174	6,500	Hold	Dipeshkumar Mehta
22-Feb-22	5,991	6,500	Hold	Dipeshkumar Mehta
20-Jan-22	6,606	6,800	Hold	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of January 17, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of January 17, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 17, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.